Processa Pharmaceuticals, Inc. (PCSA)
Oxford Ledge is still expanding full research coverage of PCSA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Processa develops modified versions of existing cancer drugs designed to reduce toxicity while maintaining therapeutic effectiveness.
SEC filings
- DEF 14A Proxy statement for shareholder vote 2026-06-18
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 10-K/A Amended annual report 2026-04-30
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-04-30
- 10-K Annual financial report with audited statements 2026-03-18
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for PCSA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open PCSA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.